Press Releases June 3, 2026 08:30 AM

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Lantheus to Participate in Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
LNTH

Lantheus Holdings, a radiopharmaceutical company, announced that John Wiggins, VP of External Manufacturing, will participate in a fireside chat at the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The event will be webcast live and available for replay, providing investor insights into the company.

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
LNTH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lantheus is a leading radiopharmaceutical company focused on improving patient outcomes through disease detection and treatment.
  • The company will feature representation at a major healthcare investor conference, signaling transparency and engagement with investors.
  • Lantheus has a global presence with offices in North America and Europe and a 70-year history in radiopharmaceuticals.

BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 9.

To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Contacts:

Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected]

Melissa Downs
Executive Director, External Communications
646-975-2533
[email protected]


Risks

  • Performance and growth projections may depend on the highly regulated healthcare and pharmaceutical sectors.
  • Market reaction could be influenced by the content and investor reception of the presentation, which remains uncertain until delivered.
  • External manufacturing and supply chain dynamics could impact operational effectiveness.

More from Press Releases

Trump Media Settles Legal Disputes Jul 19, 2026 GEnx-1B Engines Surpass 50 Million Flight Hours Jul 19, 2026 XA Investments President Kimbery Flynn Speaks to Shareholders About XFLT Proxy Vote Jul 19, 2026 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population Jul 18, 2026 UFC Names Meridian Holdings Official Sponsor of Fight Night Belgrade Jul 18, 2026